• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS One . Baseline procalcitonin as a predictor of bacterial infection and clinical outcomes in COVID-19: A case-control study

tetano

Editor, Senior Moderator
PLoS One


. 2022 Jan 13;17(1):e0262342.
doi: 10.1371/journal.pone.0262342. eCollection 2022.
Baseline procalcitonin as a predictor of bacterial infection and clinical outcomes in COVID-19: A case-control study


Natalie J Atallah[SUP] 1 2 3 [/SUP], Hailey M Warren[SUP] 1 [/SUP], Matthew B Roberts[SUP] 1 2 3 [/SUP], Ramy H Elshaboury[SUP] 4 [/SUP], Monique R Bidell[SUP] 4 [/SUP], Ronak G Gandhi[SUP] 4 [/SUP], Meagan Adamsick[SUP] 4 [/SUP], Maryam K Ibrahim[SUP] 3 [/SUP], Rupali Sood[SUP] 3 [/SUP], Savo Bou Zein Eddine[SUP] 1 5 [/SUP], Matthew J Cobler-Lichter[SUP] 6 [/SUP], Natalie J Alexander[SUP] 1 [/SUP], Kyle D Timmer[SUP] 1 [/SUP], Christine J Atallah[SUP] 7 [/SUP], Adam L Viens[SUP] 1 [/SUP], Vahe S Panossian[SUP] 8 [/SUP], Allison K Scherer[SUP] 1 2 3 [/SUP], Teddie Proctor[SUP] 9 [/SUP], Sherrie Smartt[SUP] 9 [/SUP], Alyssa R Letourneau[SUP] 1 2 3 [/SUP], Molly L Paras[SUP] 1 2 3 [/SUP], Sascha Johannes[SUP] 10 [/SUP], Jan Wiemer[SUP] 10 [/SUP], Michael K Mansour[SUP] 1 2 3 [/SUP]



Affiliations

Abstract

Purpose: Coronavirus disease-2019 (COVID-19) is associated with a wide spectrum of clinical symptoms including acute respiratory failure. Biomarkers that can predict outcomes in patients with COVID-19 can assist with patient management. The aim of this study is to evaluate whether procalcitonin (PCT) can predict clinical outcome and bacterial superinfection in patients infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
Methods: Adult patients diagnosed with SARS-CoV-2 by nasopharyngeal PCR who were admitted to a tertiary care center in Boston, MA with SARS-CoV-2 infection between March 17 and April 30, 2020 with a baseline PCT value were studied. Patients who were presumed positive for SARS-CoV-2, who lacked PCT levels, or who had a positive urinalysis with negative cultures were excluded. Demographics, clinical and laboratory data were extracted from the electronic medical records.
Results: 324 patient charts were reviewed and grouped by clinical and microbiologic outcomes by day 28. Baseline PCT levels were significantly higher for patients who were treated for true bacteremia (p = 0.0005) and bacterial pneumonia (p = 0.00077) compared with the non-bacterial infection group. Baseline PCT positively correlated with the NIAID ordinal scale and survival over time. When compared to other inflammatory biomarkers, PCT showed superiority in predicting bacteremia.
Conclusions: Baseline PCT levels are associated with outcome and bacterial superinfection in patients hospitalized with SARS-CoV-2.
 
Back
Top Bottom